Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1981 Aug 22;283(6290):537–542. doi: 10.1136/bmj.283.6290.537

Clinical pharmacology. Possible clinical importance of genetic differences in drug metabolism.

D W Nebert
PMCID: PMC1507947  PMID: 6790061

Full text

PDF
537

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baltimore D. Gene conversion: some implications for immunoglobulin genes. Cell. 1981 Jun;24(3):592–594. doi: 10.1016/0092-8674(81)90082-9. [DOI] [PubMed] [Google Scholar]
  2. Buening M. K., Chang R. L., Huang M. T., Fortner J. G., Wood A. W., Conney A. H. Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res. 1981 Jan;41(1):67–72. [PubMed] [Google Scholar]
  3. Davidson E. H., Britten R. J. Organization, transcription, and regulation in the animal genome. Q Rev Biol. 1973 Dec;48(4):565–613. doi: 10.1086/407817. [DOI] [PubMed] [Google Scholar]
  4. Frey W. A., Vallee B. L. Digitalis metabolism and human liver alcohol dehydrogenase. Proc Natl Acad Sci U S A. 1980 Feb;77(2):924–927. doi: 10.1073/pnas.77.2.924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. HUGHES H. B., BIEHL J. P., JONES A. P., SCHMIDT L. H. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc. 1954 Aug;70(2):266–273. doi: 10.1164/art.1954.70.2.266. [DOI] [PubMed] [Google Scholar]
  6. Idle J. R., Smith R. L. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev. 1979;9(2):301–317. doi: 10.3109/03602537908993896. [DOI] [PubMed] [Google Scholar]
  7. Kapitulnik J., Poppers P. J., Buening M. K., Fortner J. G., Conney A. H. Activation of monooxygenases in human liver by 7,8-benzoflavone. Clin Pharmacol Ther. 1977 Oct;22(4):475–484. doi: 10.1002/cpt1977224475. [DOI] [PubMed] [Google Scholar]
  8. Kelley W. N., Greene M. L., Rosenbloom F. M., Henderson J. F., Seegmiller J. E. Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout. Ann Intern Med. 1969 Jan;70(1):155–206. doi: 10.7326/0003-4819-70-1-155. [DOI] [PubMed] [Google Scholar]
  9. Kutt H. Biochemical and genetic factors regulating dilantin metabolism in man. Ann N Y Acad Sci. 1971 Jul 6;179:705–722. doi: 10.1111/j.1749-6632.1971.tb46946.x. [DOI] [PubMed] [Google Scholar]
  10. LEHMANN H., LIDDELL J. GENETICAL VARIANTS OF HUMAN SERUM PSEUDOCHOLINESTERASE. Prog Med Genet. 1964;23:75–105. [PubMed] [Google Scholar]
  11. Lu A. Y., West S. B. Multiplicity of mammalian microsomal cytochromes P-45. Pharmacol Rev. 1979 Dec;31(4):277–295. [PubMed] [Google Scholar]
  12. Mitchell J. R., Thorgeirsson U. P., Black M., Timbrell J. A., Snodgrass W. R., Potter W. Z., Jollow H. R., Keiser H. R. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther. 1975 Jul;18(1):70–79. doi: 10.1002/cpt197518170. [DOI] [PubMed] [Google Scholar]
  13. Nebert D. W. Genetic differences in susceptibility to chemically induced myelotoxicity and leukemia. Environ Health Perspect. 1981 Jun;39:11–22. doi: 10.1289/ehp.813911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Nebert D. W. Multiple forms of inducible drug-metabolizing enzymes: a reasonable mechanism by which any organism can cope with adversity. Mol Cell Biochem. 1979 Sep 28;27(1):27–46. doi: 10.1007/BF00849277. [DOI] [PubMed] [Google Scholar]
  15. Negishi M., Swan D. C., Enquist L. W., Nebert D. W. Isolation and characterization of a cloned DNA sequence associated with the murine Ah locus and a 3-methylcholanthrene-induced form of cytochrome P-450. Proc Natl Acad Sci U S A. 1981 Feb;78(2):800–804. doi: 10.1073/pnas.78.2.800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Neitlich H. W. Increased plasma cholinesterase activity and succinylcholine resistance: a genetic variant. J Clin Invest. 1966 Mar;45(3):380–387. doi: 10.1172/JCI105353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. O'Reilly R. A. The second reported kindred with hereditary resistance to oral anticoagulant drugs. N Engl J Med. 1970 Jun 25;282(26):1448–1451. doi: 10.1056/NEJM197006252822602. [DOI] [PubMed] [Google Scholar]
  18. OMURA T., SATO R. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964 Jul;239:2370–2378. [PubMed] [Google Scholar]
  19. Patel J. M., Harper C., Drew R. T. The biotransformation of p-xylene to a toxic aldehyde. Drug Metab Dispos. 1978 Jul-Aug;6(4):368–374. [PubMed] [Google Scholar]
  20. Patel J. M., Wood J. C., Leibman K. C. The biotransformation of allyl alcohol and acrolein in rat liver and lung preparations. Drug Metab Dispos. 1980 Sep-Oct;8(5):305–308. [PubMed] [Google Scholar]
  21. Woolhouse N. M., Andoh B., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin Pharmacol Ther. 1979 Nov;26(5):584–591. doi: 10.1002/cpt1979265584. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES